Evidence map›Paper›PMID 28751836›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2017

ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives.

Federico Nardi, Michele Massimo Gulizia, Furio Colivicchi, Maurizio Giuseppe Abrignani, Stefania Angela Di Fusco, Andrea Di Lenarda, Giuseppe Di Tano, Giovanna Geraci, Luigi Moschini, Carmine Riccio and 2 more

Abstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Federico NardiCardiology Department, S.O.C. Cardiologia, Ospedale Castelli, ASL VCO, Via Fiume 18, 28922, Verbania, Italy.
Michele Massimo GuliziaCardiology Department, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania, Italy.
Furio ColivicchiCCU-Cardiology Department, Presidio Ospedaliero San Filippo Neri, Rome, Italy.
Maurizio Giuseppe AbrignaniCCU-Cardiology Department, Ospedale Civile Sant'Antonio Abate, Erice, Trapani, Italy.
Stefania Angela Di FuscoCCU-Cardiology Department, Presidio Ospedaliero San Filippo Neri, Rome, Italy.
Andrea Di LenardaCardiovascular Center, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.
Giuseppe Di TanoCardiology Department, Azienda Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy.
Giovanna GeraciCardiology Department, Azienda Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy.
Luigi MoschiniIstituti Ospitalieri, Cardiology Unit, Cremona, Italy.
Carmine RiccioPrevention and cardiac rehabilitation Department, A.O. Sant'Anna e San Sebastiano, Caserta, Italy.
Paolo VerdecchiaInternal Medicine Unit, Ospedale di Assisi, Assisi, Perugia, Italy.
Iolanda EneaEmergency Care Department, S. Anna e S. Sebastiano Hospital, Caserta, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is now 4 years since the introduction of the new direct oral anticoagulants into clinical practice. Therefore, the Italian Association of Hospital Cardiologists (ANMCO) has deemed necessary to update the previous position paper on the prevention of thrombo-embolic complications in patients with non-valvular atrial fibrillation, which was published in 2013. All available scientific evidence has been reviewed, focusing on data derived from both clinical trials and observational registries. In addition, all issues relevant to the practical clinical management of oral anticoagulation with the new direct inhibitors have been considered. Specific clinical pathways for optimal use of oral anticoagulation with the new directly acting agents are also developed and proposed for clinical implementation. Special attention is finally paid to the development of clinical algorithms for medium and long-term follow-up of patients treated with new oral direct anticoagulants.

Indexed as

AnticoagulationApixabanAtrial fibrillationDabigatranEdoxabanRivaroxaban

Identifiers

PMID28751836
PMCPMC5526472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.